Ascendia and AcuteBio are establishing an improved treatment method for coronary artery disease (CAD). It is particularly beneficial for stent placements. For example, an oral dose has a two- to five-hour onset of action, while an IV delivery allows for immediate onset of action, so stents can be inserted to remove blockages in significantly less time. The FDA IND approval validates Ascendia Pharma's EmulSol technology platform.
"The idea of a clopidogrel IV formulation advancing to a Phase 1 human clinical study is important, as clopidogrel is the recognized gold standard that will lead to better quality of life for patients. Many other reputable pharmaceutical companies have attempted to develop such a formulation but have been unsuccessful. Our achievement is another milestone that hallmarks how Ascendia Pharmaceuticals continues to Make the Impossible Possible by leveraging our nanotechnologies," said Dr. Huang. "We look forward to assisting AcuteBio advance this delivery method to market."
EmulSol is one of four proprietary nanotechnology platforms developed by Ascendia. The others are AmorSol®, NanoSol®, and LipidSol®. These nanotechnologies represent tremendous advantages in drug development and have proven track records in overcoming bioavailability, solubility, and stability challenges.
Read the original article on PR Newswire.
